Plné znění - 2/2008 Sb. m. s.

Xxxxxxxxxxxx zahraničních xxxx xxxxxxx, xx xxx 16. xxxxxxxxx 2007 xxxx xxxxxxxxxx xxxxxxxxx XXXXXX, depozitářem Xxxxxxxxxxx xxxxxx xxxxx xxxxxxx xx xxxxxx¹⁾, xxxxxxxx schválení xxxxxx xxxxx Přílohy I - Xxxxxxx xxxxxxxxxx látek x xxxxx dopingu.

Xxxxxxx X xxxxxxxxx x xxxxxxxx v xxxxxxx x článkem 34 xxxx. 3 Xxxxxx xxx 1. ledna 2008 x xxxxx xxxx xxxxxxxxx v xxxxxxxx i xxx Xxxxxx xxxxxxxxx. Dnem xxxxxx Xxxxxxx X x xxxxxxxx přestává xxxxxx Xxxxxxx I Xxxxxxxxxxx xxxxxx xxxxx xxxxxxx xx xxxxxx xx xxxxx xxx xxx 2007, vyhlášená xxx x. 59/2007 Xx. x. s.

Xxxxxxxx znění Xxxxxxx X a její xxxxxxx xx xxxxxxx xxxxxx xx xxxxxxxxx xxxxxxxx.

X1. ANABOLICKÉ XXXXX

Xxxxxxxxxx látky xxxx xxxxxxxx.

1. ANDROGENNÍ XXXXXXXXXX STEROIDY (AAS):

x. Xxxxxxxx * XXX, xxxxxxxxxx:

1-xxxxxxxxxxxxx (5α-xxxxxxx-1-xx-3β,17β-xxxx); 1-androstendion (5α-androst-1-en-3,17-dion); xxxxxxxxx (19-xxxxxxxxxxxxxxxx); bolasteron; xxxxxxxx; boldion (xxxxxxxx-1,4-xxxx-3,17-xxxx); xxxxxxx (17α-xxxxxxx-17β-xxxxxxxxxxxxxx-4-xxx[2,3-x]xxxxxxxx); dehydrochlormethyltestosteron (4-xxxxxx-17β-xxxxxxx-17α-xxxxxxxxxxxxx-1,4-xxxx-3-xx); desoxymethyltestosteron (17α-xxxxx-5α-xxxxxxx-2-xx-17β-xx); xxxxxxxxxxx; ethylestrenol (19-xxx-17α-xxxxx-4-xx-17-xx); xxxxxxxxxxxxxx; formebolon; furazabol (17β-xxxxxxx-17α-xxxxx-5α-xxxxxxxxxx[2,3-x]-xxxxxxx); xxxxxxxxx; 4-xxxxxxxxxxxxxxxxxx (4,17β-xxxxxxxxxxxxxxxx-4-xx-3-xx); xxxxxxxxxx; xxxxxxxxx; xxxxxxxxxx; mesterolon; xxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxxxxxx-1,4-xxxx-3-xx); metenolom; xxxxxxxxxxx; xxxxxxxxxx (2α, 17α-xxxxxxx-5α-xxxxxxxxx-3-xx-17β-xx); xxxxxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxxx-4,9-xxxx-3-xx); xxxxxx-1-xxxxxxxxxxx (17β-xxxxxxx-17α-xxxxx-5α-xxxxxxx-1-xx-3-xx); xxxxxxxxxxxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxx-4-xx-3-xx); xxxxxxxxxxxxxxx (17β-hydroxy-17α-metylestra-4,9,11-trien-3-on); xxxxxxxxxxxxxxxxx; xxxxxxxxx; xxxxxxxxx; 19-norandrostendion (xxxx-4-xx-3,17-xxxx); xxxxxxxxxx; xxxxxxxxxxxxxx; xxxxxxxxxxxx; xxxxxxxx; oxandrolon; xxxxxxxxxxx; oxymetolon; xxxxxxxxxxx ([3,2-x]xxxxxxx-5α-xxxxxxxxxxxxxx-17β-xxxxxxxxxxxxxxxxx); quinbolon; xxxxxxxxxx; xxxxxxxxx; 1-testosteron (17β-hydroxy-5α-androst-1-en-3-on); xxxxxxxxxxxxxxxxxxx (18α-homo-pregna-4,9,11-trien-17β-ol-3-on); xxxxxxxxx x další xxxxx x xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx.

x. Xxxxxxxxx ** AAS:

Xxxxxxxxxxxxx (androst-5-en-3β,17β-diol), xxxxxxxxxxxxx (xxxxxxx-4-xx-3,17-xxxx), xxxxxxxxxxxxxxxxxx, xxxxxxxxx (xxxxxxxxxxxxxxxxxxxxx, DHEA), xxxxxxxxxxx x následující metabolity x xxxxxxx:

5α-androstan-3α,17α-diol androst-5-en-3β,17α-diol

5α-xxxxxxxxx-3α,17β-xxxx 4-xxxxxxxxxxxxx (androst-4-en-3β,17β-diol)

5α-xxxxxxxxx-3β,17α-xxxx 5-xxxxxxxxxxxxx (xxxxxxx-5-xx-3,17-xxxx)

5α-xxxxxxxxx-3β,17β-xxxx xxx-xxxxxxxxxxxxxxxxxx

androst-4-en-3α,17α-diol 3α-hydroxy-5αandrostan-17-on

xxxxxxx-4-xx-3α,17β-xxxx 3β-xxxxxxx-5αxxxxxxxxx-17-xx

xxxxxxx-5-xx-3β,17α-xxxx 19-xxxxxxxxxxxxxx

xxxxxxx-5-xx-3α,17α-xxxx 19-xxxxxxxxxxxxxxxxx

androst-5-en-3α,17β-diol

X xxxxxxxxx, xxx xxxx xxxx produkovat xxxxxxxxxx xxxxxxxxxx xxxxxxx xxxxxxxxx, xxxx xx xxx xx xx, že Xxxxxx xxxxxxxx tuto Xxxxxxxxx xxxxx x xxxx hlášen pozitivní Xxxxxxxxx xxxxxxxxxxx xxxxx, xxxx xx xxxxxxxxxxx Xxxxxxxx xxxxx xxxx xxxxxx metabolitů xxxx xxxxxxxxxxx x/xxxx xxxx xx jakýkoli jiný xxxxxxxxx xxxxx xx Xxxxxx Xxxxxxxxx významně xxxxxxxxx xx xxxxxxx xxxxxx, xxxxx xx xxxxxxxx xxxxxxxxx x xxxx tak, xx xxxxxxxxxx xxxxxxxx endogenní xxxxxxxx. Xxxxxx se xxx xx xx, xx Xxxxxx obsahuje Xxxxxxxxx xxxxx x xxxxxxx případě, xxxxx Xxxxxxxxx xxxxxxx, že xx xxxxxxxxxxx Xxxxxxxx xxxxx xxxx xxxxxx xxxxxxxxxx xxxx xxxxxxxxxx x/xxxx xxxxxxxxx xxxxx xx Xxxxxx Xxxxxxxxx xxxxxxxx xxxxxxxxxxxxx xxxx xxxxxxxxxxxx stavem.

Xxxx xx xxx xx xx, xx Xxxxxx Xxxxxxxxx obsahuje Xxxxxxxxx xxxxx x laboratoř xxxxxxx Pozitivní laboratorní xxxxx xx xxxxx xxxxxxxxx a xxx xxxxxxxxx xxxxxxxxxxx, xxxxx xxx xxxxx xxxxxxxxxx xxxxxxxxxx xxxxxx (xxxx. XXXX) xxxxxxxx, xx xx Zakázaná látka xxxxxxxxxx xxxxxx. X xxxxxxx xxxxxxx není xxxxx xxxxxxxx další xxxxxxx.

Když xx xxxxxxx xxxxxxxx xxxxxxx xxxxxxxx xxxxxxxxxxx xx xxxxxxx xxxxxx, xxxxx xx xxxxxxxx vyskytují x xxxx x xxxxx spolehlivá xxxxxxxxxx xxxxxx (xxxx. IRMS) xxxxxxxxxxx exogenní xxxxx Xxxxxxxx xxxxx, ale xxxxxxxx xxxxxx xxxxxxx Xxxxxxxx látky, xxxx xxxx. porovnání x xxxxxxxxxxx referenčními steroidními xxxxxxx, xxxx xxxx xxxxxxxxx xxxxxxxxx xxxxx X/X xxxxx xxx xxxxx (4) xx xxxxx (1) x xxxxx xxxxxxxxxx xxxxxxxxxx xxxxxx (např. IRMS) xxxxxxxxxxx xxxxxxxx původ xxxxx, xxxxxxx xxxxxxxxx Xxxxxxxxxxxxx xxxxxxxxxx xxxxx xxxxxxx xxxxxxxxxx xxxxxxxx xxxxxxxxxx testů xxxx xxxxxxxxxx xxxxxxxxxx testů.

Xx-xx xxxxxxxxxx xxxxxx xxxxx šetření, pak xxxxxxxx xxxx laboratoří xxxxxx jako neobvyklý x ne jako xxxxxxxxx. Pokud xxxxxxxxx xxxxxxx, xx xxxxxxx xxxxxxxxxx xxxxxxxxxx metody (xxxx. IRMS) exogenní xxxxx Zakázané xxxxx, xxxx xxxxx xxxxxxxx xxxxx šetření, x xxxx se mít xx xx, že Xxxxxx xxxxxxxx Xxxxxxxxx xxxxx. Xxxxx xxxxxx xxxxxxx xxxxxxxxxx xxxxxxxxxx xxxxxx (xxxx. XXXX) x nejsou k xxxxxxxxx minimálně 3 xxxxxxxxx xxxxx, bude xxxxxxx longitudinální xxxxxx Xxxxxxxxx xxx, xx xxxx xxxxxxxxxx Antidopingovou xxxxxxxxxx x následujících 3 měsících xxxxxxx xxxxxxxx xxx xxxxxxxxxxx xxxxxxxx. Výsledek, který xxxxxxxxxx tuto longitudinální xxxxxx, xxxx xxxxxx xxxx xxxxxxxxx. Pokud xxxxxxxxxxxxxx profil Sportovce, xxxxxxxx následnými xxxxx, xxxx fyziologicky xxxxxxxx, xxxx xx xxx xxxxxxxxx za Xxxxxxxxx xxxxxxxxxxx nález.

V xxxxxxxx xxxxxxxx xxxxxxxxxxxxxx xxxxxxxxx xxxx xxx x moči xxxxxx xxxxxxx xxxxxxxx endogenního xxxxxx xx velice xxxxxx koncentracích (xx/xx). Xxxxx xxxxxxxxx xxxxxx xxxxx xxxxxxxxx a xxxxxxx xxxxxxxxxx analytické xxxxxx (xxxx. IRMS) xxxxxxxxxxx xxxxxxxx původ Xxxxxxxx látky, xxxx xxx xxxxxxxxx xxxxx xxxxxxx provedením xxxxxxxxxx xxxxx (následných xxxxx).

Xxxxx xxxxxxxxx xxxxxxxxx Xxxxxxxxx xxxxxxxxxxx xxxxx 19-xxxxxxxxxxxxxxx, bude xx xx považovat za xxxxxxx a xxxxxxxxxxx xxxxx xxxxxxxxxx původu Xxxxxxxx xxxxx. V xxxxxxx případě xxxx xxxxx provádět další xxxxxxx.

X případě, xx Sportovec nebude xxxxxxxxxxxxx při xxxxxxx xxxxxxxxx, xxxx xx xxx xx to, xx Xxxxxx Sportovce xxxxxxxx Xxxxxxxxx xxxxx.

2. Xxxxxxx xxxxxxxxxx xxxxx, xxxxxxxxxx:

Xxxxxxxxxxx, xxxxxxxxxx modulátory androgenových xxxxxxxxx (XXXX), xxxxxxx, xxxxxxx, zilpaterol, xxx xx x omezením xxxxx na xx.

X2. XXXXXXX A XXXXXXXX XXXXX

Následující xxxxx x xxxxxx xxxxxxxxxx xxxxxxx xxxx xxxxxxxx:

1. Erytropoetin (EPO);

2. Růstový hormon (xXX), xxxxxxxx podobné xxxxxxx faktory (xxxx. XXX-1), mechanické xxxxxxx xxxxxxx (XXX);

3. Xxxxxxxxxxxxx (xxxx. XX, xXX), zakázané jen x xxxx;

4. Xxxxxxxx;

5. Xxxxxxxxxxxxxx

x xxxxx xxxxx x podobnou chemickou xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx.

Xxxxx Xxxxxxxxx xxxxxx xxxxxxxx, xx xxxxxxxxxxx byla xxxxxxxxx fyziologickým xx xxxxxxxxxxxx xxxxxx, bude xx xxx za xx, xx Vzorek xxxxxxxx Xxxxxxxxx xxxxx (xxx xx xxxxxxx xxxx) v xxxxxxxxx, xxx xxxxxxxxxxx Xxxxxxxx xxxxx xxxx xxxxxx xxxxxxxxxx xx xxxxxxxxxx x/xxxx xxxxxxxxx xxxxxx xx Xxxxxx Xxxxxxxxx xxxxxxx xxxxxxxx xxxxxxx xxxxxxxx zjištěné x xxxx tak, že xxxxxxxxxxxx xxxxxxxx endogenní xxxxxxxx.

Pokud laboratoř xxxxxxxxx, xx xxxxx xxxxxxxxxx xxxxxxxxxx xxxxxx, xx Xxxxxxxx xxxxx xx exogenního xxxxxx, xxxx xx mít xx xx, že Xxxxxx xxxxxxxx Xxxxxxxxx xxxxx a xxxx xxxxxxx Xxxxxxxxx laboratorní xxxxx.

X3. XXXX-2 XXXXXXXX

Xxxxxxx xxxx-2 agonisté xxxxxx xxxxxx D- x X-xxxxxxx xxxx xxxxxxxx.

Xxxxxxxx xxxx formoterol, xxxxxxxxxx, xxxxxxxxxx x xxxxxxxxxx, pro xxxxx xx xxx xxxxxxxx xxxxx udělení xxxxxxxx xxxxxxxxxxxx xxxxxxx.

X xxxx xxxx xxxxxxx xxxxxxxx xxxxx terapeutické xxxxxxx, xxxx nález xxxxxxxxxxx (xxxxx xxxx xxxxxxxxxx) xxxxx xxx 1000 xxxxxxxxx x 1 xxxxxxxxx xxxx xxxxxxxxx za Xxxxxxxxx xxxxxxxxxxx nález, xxxxx Xxxxxxxxx neprokáže, že xxxxxxxxxx xxxxxxxx xxx xxxxxxxx terapeutickým xxxxxxxx xxxxxxxxxxx x xxxxxxxx.

X4. XXXXXXXXXXX X XXXXXXXXXX HORMONŮ

Xxxxxxxxxxx xxxxxxx xxxx xxxxxxxx:

1. Inhibitory xxxxxxxx, xxxxxxxxxx:

2. Xxxxxxxxxx xxxxxxxxxx xxxxxxxxxxxxx receptorů (XXXX), xxxxxxxx:

3. Xxxxxxx antiestrogenní xxxxx xxxxxxxxxx:

4. Xxxxx modifikující xxxxxx xxxxxxxxxx xxxxxx inhibitorů xxxxxxxxxx, xxx ne x omezením xxxxx xx xx.

X5. XXXXXXXXX A XXXXXXX MASKOVACÍ XXXXX

Maskovací xxxxx xxxx xxxxxxxx. Xxxxxxxx:

Xxxxxxxxx*, xxxxxxxxxxxxxx, xxxxxxxxxx, xxxxxxxxxx xxxx-xxxxxxxxx (xxxx. xxxxxxxxxx, dutasterid), xxxxxxxxxxxxxxx (xxxx. xxxxxxx, dextran, xxxxxxxxxxxxxxxxx) a další xxxxx x podobnými xxxxxxxxxxxx účinky.

Xxxxxxxxx xxxxxxxx:

Acetazolamid, xxxxxxxx, xxxxxxxxx, xxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxx, xxxxxxxx, xxxxxxxx xxxxxxxxxx, xxxxxxxxx, spironolakton, xxxxxxxx (xxxx. bendroflumethiazid, xxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxx), xxxxxxxxxx x xxxxx xxxxx x podobnou xxxxxxxxx xxxxxxxxxx nebo xxxxxxxxx xxxxxxxxxxxx účinky (xxxxx xxxxxxxxxxxx, který xxxx xxxxxxxx).

* Xxxxxxxxxxxx xxxxxxx xxxx platná, xxxxx moč Xxxxxxxxx xxxxxxxx xxxxxxxxx xx xxxxxxx x prahovou xxxx xxxxxxxxxxx hladinou xxxx Xxxxxxxx xxxxx (xxxxx).

X1. ZVYŠOVÁNÍ XXXXXXX XXXXXXX

Xxxxxxxx xx xxxxxxxxxxx:

M2. XXXXXXXX X XXXXXXXXX XXXXXXXXXX

X3. XXXXXX XXXXXX

Xxxxxxxxxxxxxx xxxxxxx xxxxx, genů, xxxxxxxx xxxxxxxx, nebo xxxxxxxxxx xxxxxxx xxxx, xxxxx xxxx schopnost xxxxxx sportovní xxxxx, xx xxxxxxxx.

X6. STIMULANCIA

Xxxxxxx xxxxxxxxxxx (včetně xxxx xxxxxx xxxxxxxxxx xxxxxxxxx (X- x X-) xxxxxxx) jsou xxxxxxxx, x xxxxxxxx derivátů xxxxxxxxx x případě xxxxxx xxxxxxxx xxxxx x xxxxxxxxxxx xxxxxxxxxx xx Xxxxxxxxxxxxxx xxxxxxxx xxx xxx 2008.

Xxxxxxxxxxx xxxxxxxx:

Xxxxxxxxx, xxxxxxxxx**, amfepramon, xxxxxxxxxxx, xxxxxxxxxx, amfetamin, xxxxxxxxxxx, xxxxxxxxxxxxxxx, xxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxxxxxxxx, xxxxxxx****, xxxxxxxx, xxxxxxxxx, xxxxxxxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxx, fenkamfamin, xxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxxx, xxxxxxxxxxx, xxxxxxxxx, 4-xxxxxxxxxxxxxx (karfedon), xxxxxxxxxx, heptaminol, xxxxxxxxxxxx, xxxxx***, xxxxxxxxxxx, xxxxxx, xxxxxxxxxxx, krotetamid, xxxxxxxxxxxxxxx, xxxxxxxxx, mefentermin, xxxxxxxxxxxx, xxxxxxxxxxxx (D-), xxxxxxxxxxxx****, xxxxxxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxx, xxxxxxxx, xxxxxxxxx, xxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxxxx, xxxxxxxxx, xxxxxxxxx, xxxxxxxxx, xxxxxxxxxxxxxxxxxxxx, xxxxxxx, xxxxxxxxxxx, p-methylamfetamin, xxxxxxxxx, propylhexedrin, selegilin, xxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxxxx x xxxxx látky x xxxxxxxx chemickou xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx.

Xxxxxxxxxxxx neuvedené výslovně xxxx xxxxxxxx x xxxxx xxxxxx bude xxxxxxxxxx xx specifickou xxxxx xxxxx, xxxxx Xxxxxxxxx xxxxxxx, xx xxxx xxxxxxxxx dostupnost x xxxxxxx xxxxxxxxx xxxxxxxxxxx umožňuje xxxxxxxxx xxxxxxxx antidopingových xxxxxxxx, xxxx je x xxx xxxxx xxxxxxxxxxxxxxx, xx xxxx úspěšně xxxxxxxx xxxx xxxxxxxxx xxxxx.

X7. XXXXXXXXX

Xxxxxxxxxxx narkotika xxxx zakázaná:

Xxxxxxxxxxx, xxxxxxxxxxxxx, xxxxxxxxx(xxxxxx), fentanyl x jeho xxxxxxxx, xxxxxxxxxxx, xxxxxxx, xxxxxx, xxxxxxxx, oxymorfon, xxxxxxxxxx, xxxxxxx.

X8. XXXXXXXXXXX

Xxxxxxxxxxx (xxxx. xxxxx, xxxxxxxxx) xxxx xxxxxxxx.

X9. XXXXXXXXXXXXXXXXXXXX

Xxxxxxx xxxxxxxxxxxxxxxxxxxx xxxxxxxx xxxxxx, xxxxxxxx, xxxxxxxxxx xxxx xxxxxxxxxxxxx xxxxxxxx xxxx xxxxxxxx. Xxxxxx xxxxx xxxxxxxx xxxxxxxxxxxxx výjimku.

Xxxx xxxxxxx xxxxxxxx xxxxxxxx (xxxxxxxxxxxx, xx okolí xxxxxx, xx okolí xxxxxx, xxxxxxxxxx, do xxxx) x inhalační xxxxxxxx xxxxxxxx xxxxxxxxx xxxxxxxxxxxxx výjimku x xxxxxxxx níže xxxxxxxxx.

Xxxxxxx xxxxxxxxx xxxxxxxx xx potíže xxxxx (xxxxxx xxxxxxxxxxx/xxxxxxxxxx), ušní, xxxxx, xxxx, xxxxxx xxxxx xxxxxxx otvoru, xxxxxxxx xxx x xxxxx nejsou xxxxxxxx x nevyžadují xxxxxx xxxxx xxxxxxxxxxxx výjimky.

X1. XXXXXXX

Xxxxxxx (xxxxxx) xx xxxxxxxx pouze Xxx xxxxxxx x xxxxxxxxxxxxx sportech. Xxxxxxx xx xxxx xxxxxxxx xxxxxxxx xxxxxxxx a/nebo xxxxxxxx xxxx. Xxxxxxx xxxxxxx xxx xxxxxxxx xxxxxxxxxxx xxxxxxxx (xxxxxxxxxxxxx xxxxxxx) je xxx xxxxxx xxxxxxxx xxxxxxx x xxxxxxxxx.

∙ Xxxxxxxxxxxx xxxxx (FIA) (0.10 g/l)

∙ Xxxxxx (XXX) (0.10 x/x)

∙ Letecké xxxxxx x xxxxxxxxxxxx (XXX) (0.20 x/x)

∙ Lukostřelba (FITA, XXX) (0.10 g/l)

∙ Xxxxxxx xxxxxxx (XXXX) xxx pro xxxxxxxxxx xx střelbou (0.10 g/l)

∙ Xxxxxxxxxxx sport (XXX) (0.10 g/l)

∙ Xxxxx xxxxxxxxxx (XXX) (0.30 x/x)

∙ Kuželky (IPC) (0.10 x/x)

X2. BETA-BLOKÁTORY

Xxxxx xxxx xxxxx xxxxxx, xxxx-xxxxxxxxx xxxx xxxxxxxx xxxxx Xxx xxxxxxx x xxxxxxxxxxxxx sportech.

∙ Xxxxxxxxxxxx xxxxx (XXX)

∙ Xxxxxxxx (XXXX)

∙ Boby (XXXX)

∙ Bridž (XXX)

∙ Xxxxxxx (XXX)

∙ Xxxxxxxxxx (XXX)

∙ Jachting (XXXX) - "xxxxx xxxx" - jen xxxxxxxxxxx

∙ Kuželky (XXX)

∙ Xxxxxxx xxxxxx x xxxxxxxxxxxx (XXX)

∙ Lukostřelba (XXXX, XXX) (zakázané xxxx Xxxx xxxxxx)

∙ Xxxxxxxx (XXX) - xxxxx xx xxxxxx a xxxxxxxxxxx xxxxxxxx-xxxxx a X-xxxxx, x snowboard X-xxxxx x "xxx xxx"

∙ Xxxxxxx xxxxxxx (XXXX) - jen xxxxxxxxxx xx střelbou

∙ Motocyklový xxxxx (XXX)

∙ Xxxxxxxx x obdobné sporty (XXXX, IPC "bowls")

∙ Xxxxxxx (XXXX, XXX) (xxxxxxxx xxxx Xxxx xxxxxx)

∙ Xxxxx xxxxxxxxxx (XXX)

∙ Xxxxx (XXXX)

Xxxx-xxxxxxxxx xxxxxxxx xxxxxxxxxxx xxxxx:

Xxxxxxxxxx, alprenolol, xxxxxxxx, xxxxxxxxx, xxxxxxxxxx, xxxxxxx, xxxxxxxxxx, xxxxxxx, xxxxxxxxx, xxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxxx, xxxxxxx, oxprenolol, xxxxxxxx, xxxxxxxxxxx, xxxxxxx, xxxxxxx, xxx xx s xxxxxxxx xxxxx xx xx

"Xxxxxxxxxx xxxxx"* xxxx xxxxxxxxxxx xxxx:

∙ Xxxxxxx Xxxx-2 xxxxxxxx v xxxxxxxx, xxxxx xxxxxxxxxxx (xxxxxxx xxxx xxxxxxxxxxx) xxx xxxxxxxx xxxxxx xxx 1000 xx/xx xxxx x clenbuterolu (xxxxxxx xx xxxxxxx X 1.2 Xxxxxxx anabolické xxxxx);

∙ Inhibitory xxxx-xxxxxxxxx, xxxxxxxxxx;

∙ Xxxxx, xxxxxxxxxxx, xxxxxxxxxx, xxxxxxx, xxxxxxxx, famprofazon, xxxxxxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxxxxxxxx, xxxxxxxxxxxx, x-xxxxxxxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxx, xxxxxxxxx, ortetamin, xxxxxxxxx, xxxxxxxxxxxxxx, selegilin, xxxxxxxxxx, xxxxxxxxxxxxx x xxxxxxx xxxxxxx xxxxxxxxxxx xxxxxxxxx xxxxxxxx x oddíle X6, pro která Xxxxxxxxx xxxxxxx, xx xxxxxxx podmínky xxxxxxx x oddíle X6;

∙ Kanabinoidy;

∙ Xxxxxxx Xxxxxxxxxxxxxxxxxxxx;

∙ Xxxxxxx;

∙ Všechny Xxxx-xxxxxxxxx.

*"X Xxxxxxx xxxxx xxx xxxxxxxxxxx xxxxxxxxxx xxxxx, které xxxxxxxx xxxxxxxx xxxxxxxxx xxxxxxxx xxxxxxxxxxxxxxx xxxxxxxx, xxxxxxx jsou xxxxxxxxx xxxxxxxx v běžných xxxxxxxxx přípravcích, nebo x nichž xx xxxxx xxxxxxxxxxxxxxx, xx xxxxx xxxxxxx xxxxxxxx xxxx xxxxxxxxx xxxxxxx." Xxxxxxxx xxxxxxxxxxxxxxx xxxxxxxx xxxxxxxxxx xxxxxxxx látky xxxx xxxxxxxx snížený xxxxxx za předpokladu, xx "...Xxxxxxxxx xxxx xxxxx prokázat, xx Xxxxxxx xxxxxxxxxx xxxxx xxxxxx xxxxxxxxx xx xxxxxxx xxxxxxxxxxx xxxxxx...".

Xxxxxx xxxxxxx č. 2/2008 Sb. x. x. nabyl xxxxxxxxx xxxx 31.1.2008.

Xxxxxx xxxxxxx č. 2/2008 Xx. m. x. xxx xxxxxx xxxxxxx předpisem č. 8/2009 Sb. m. s. x účinností od 7.2.2009.

Xxxxx xxxxxxxxxxxx xxxxxxxx xxxxx xxxxxx právních xxxxxxxx x xxxxxxxx xxxx xxxxxxxxxxxxx, pokud xx xxxx netýká xxxxxxxxx xxxxx shora uvedeného xxxxxxxx xxxxxxxx.